Blogs and News

This month we celebrate a milestone for Siron Clinical: 20 years of success as a CRO. We couldn’t be prouder of our rich history, accolades and accomplishments that define our business and help us to stand out as a local CRO with a global mindset. To mark this...

If you follow Siron Clinical on social media, you may have noticed that we have been sharing news, opinions and information about the Coronavirus pandemic in relation to clinical research, particularly in terms of how it’s affecting trials. The pandemic was...

We recently published a downloadable RFI which details our extensive experience with clinical trials in Europe. read highlights from the RFI document in the info-graphic, and discover how we define clinical trail success in Europe.

Clinical trials are unique, each with their own protocol, parameters, participants and therapeutic areas. They can differ greatly, covering a range of treatment and study types, and subject to different local regulations and cultural factors. So how do you know what defines success?

As the COVID-19 pandemic continues, day after day we are inundated with information. For the CRO industry, the message is that measures are in place and everything is under control; remote meeting and monitoring capabilities are keeping trials ticking over. This is true, but it’s only part of the story. In reality, remote monitoring is limited, as CRAs do not have access to source documents.

This will leave a backlog in monitoring that will have a significant impact when we reach the ‘new normal’. Everyone should be prepared, not just for this inevitable backlog, but also for the studies you have planned for the future.

I would like to begin by saying I hope you and your family are staying safe and healthy during this uncertain time. I know the COVID-19 pandemic is having an impact, both professionally and personally, on everyone.

Clinical trials come with vast amounts of information, and a new partnership between Siron Clinical and Montrium will ensure clients benefit from efficient and effective trial information management in an increasingly digitized clinical research industry.

An estimated 1 in 50 children over the age of 4 are allergic to peanuts; a new immunotherapy now approved by the FDA, following phase III trials carried out with support from Siron Clinical, will help increase their tolerance to peanuts and reduce their risk of anaphylaxis.

BIO-Europe attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors and other industry experts. It is a unique opportunity to meet potential partners and suppliers through one-to-one meetings.

For the past 20 years, Siron Clinical has provided a high level of expertise in clinical trials for biotechs. Discover our Siron Clinical rebrand journey.